Fintel · Aug 8, 2026
DN
NYSE · DNA
Ginkgo Bioworks Holdings, Inc.
Healthcare · Biotechnology
$7.40
Up+$0.44 (+6.32%)
Updated Aug 22, 2026, 8:43 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 539.91M
- P/E ratio
- -1.62
- Dividend yield
- 0.00%
- 52-week range
- $5.37 – $17.58
- Volume
- 1.44M
- Avg. volume
- 1.4M
Price performance
DNA price history
1M range · 0 trading sessions · Daily adjusted prices
DNA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest DNA news
The latest Smart Investors Daily articles mentioning DNA.
Stock researchCompany · Overview
DNA research
Overview
Company profile and research snapshot.
Company profile
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | TD Cowen | Hold | — |
| Mar 12, 2026 | BTIG | Sell | — |
| Jan 8, 2026 | TD Cowen | Buy | — |
| Aug 25, 2025 | BTIG | Sell | — |
| Sep 20, 2024 | TD Cowen | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
TD Cowen Downgrades Ginkgo Bioworks Holdings to Hold, Lowers Price Target to $9
TD Cowen analyst Brendan Smith downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Buy to Hold and lowers the price target from $12 to $9.
SeekingAlpha · Aug 6, 2026
Ginkgo Bioworks Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-06. The following slide deck was published by Ginkgo Bioworks Holdings, Inc.
SeekingAlpha · Aug 6, 2026
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsDaniel Marshall - Senior Manager of Communications...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
